News & Events


Trisalus life sciences’ pressure-enabled drug delivery (PEDD) significantly increased therapeutic effect of anti-CEA CAR-T in pancreatic cancer patients with liver metastases

CAMBRIDGE, MA—November 7, 2018—A phase 1b clinical trial shows that administering a concentrated dose of anti-CEA CAR-T cells precisely at the site of a solid tumor by means of TriSalus™Life Sciences’unique Pressure-enabled Drug Delivery (PEDD) is safe, with encouraging clinical responses.

Phasellus eleifend ipsum sem, ut mattis nunc eleifend ac. Ut nisi libero, aliquam nec blandit quis, pulvinar ut sapien. Fusce sed massa faucibus, commodo leo eu, euismod ante. Suspendisse pellentesque ipsum eu eleifend ultrices. Aenean ac lacus eu elit pretium ultricies id ut nisl. Vestibulum dapibus eget lectus a tempor. Suspendisse potenti. Nunc commodo turpis mi. In tincidunt nibh in urna malesuada, eu laoreet urna vehicula. Cras fringilla tincidunt dolor, hendrerit feugiat sem feugiat non. Morbi fringilla nunc id sem porttitor, non faucibus massa pharetra.

Praesent pretium tincidunt orci gravida laoreet. Morbi cursus fringilla fringilla. Nunc in auctor purus. Phasellus odio justo, malesuada nec libero non, tincidunt facilisis tortor. Pellentesque venenatis sagittis posuere. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nulla sollicitudin felis nisi, vel sollicitudin ipsum blandit non. Nam imperdiet tincidunt purus eget suscipit. In sed urna eget elit iaculis varius. Nam mollis imperdiet lacus, sed congue tortor hendrerit at. Integer a fringilla metus, id faucibus mauris. Nulla vel magna sed ante consequat tempor eget vestibulum ex. Aenean rhoncus semper tortor, sed egestas lacus facilisis mollis. Sed placerat sapien ac nisi tempus lacinia. Sed pellentesque commodo diam non semper.

About TriSalus™ Life Sciences

TriSalus Life Sciences is committed to transforming outcomes for patients with pancreatic cancer and other solid tumors. Our solution is bold: to integrate novel and proprietary therapeutics with the TriSalus Pressure-Enabled Drug Delivery™ (PEDD™) technology. It’s a comprehensive approach intended to improve treatment response and, ultimately, outcomes.

The PEDD platform increases drug concentration in the tumor by generating favorable pressure to overcome the infusion barriers of the tumor microenvironment. The integration of PEDD with chemotherapy, immunotherapy, and other emerging therapies may improve treatment efficacy while reducing the toxicity challenges of traditional delivery methods.

Acknowledging that meaningful progress in this difficult-to-treat disease is not easy, we’re committed to transforming the battle with pancreatic cancer through deep science, novel technology innovation, and an absolute focus on the patient.

For more information, please visit

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology (I-O) platforms, including key assets such as fully human antibodies (G-MAB™ library), clinical-stage immunocellular therapies (CAR-T), intracellular targeting antibodies (iTAbs), antibody-drug conjugates (ADCs), and clinical-stage oncolytic virus (Seprehvir®).

Sorrento’s commitment to life-enhancing therapies for cancer patients and osteoarthritis (OA) patients is also demonstrated by its effort to advance Resiniferatoxin (RTX), a first-in-class (TRPV1 agonist) nonopioid pain management small molecule, ZTlido® and SP-102, a nonopioid corticosteroid gel. Resiniferatoxin is completing a Phase 1b trial in terminal cancer patients and a Phase 1b trial for OA. ZTlido was approved by US FDA on 02/28/18. SP-102 (Semdexa™) is in Phase 3 pivotal study for the treatment of lumbar radicular pain/sciatica.

For more information, visit
More information on Sorrento clinical trials can be found at